Kevin A Lynch

US Patent:

6395530, May 28, 2002

Filed:

Dec 5, 1997

Appl. No.:

08/985492

Inventors:

Michael C. Jaye - Glenside PA
Kim-Anh Thi Doan - Audubon PA
John A. Krawiec - Gulph Mills PA
Kevin J. Lynch - Gurnee IL
Dilip V. Amin - Lansdale PA
Victoria J. South - Collegeville PA

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

C12N 920

US Classification:

435198, 536 231, 536 232, 4353201, 435325

Abstract:

Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.

US Patent:

7008776, Mar 7, 2006

Filed:

Mar 26, 1999

Appl. No.:

09/277401

Inventors:

Michael Jaye - Glenside PA, US
Kim-Anh Thi Doan - Spring City PA, US
John A. Krawiec - Gulph Mills PA, US
Kevin J. Lynch - Gurnee IL, US
Dilip V. Amin - Lansdale PA, US
Victoria J. South - Collegeville PA, US
Dawn Marchadier - Sickelerville NJ, US
Cyrille Maugeais - Philadelphia PA, US
Daniel J. Rader - Collegeville PA, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ
The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

G01N 33/573
C12N 9/20

US Classification:

435 74, 435198

Abstract:

The present invention relates to compositions for use in raising or lowering the level of LIPG polypeptide in a patient. Embodiments of the composition include compositions comprising: an anti-sense nucleic acid; a neutralizing antibody; an intracellular binding protein; an inhibitor which inhibits the enzymatic activity of LIPG polypeptide; an inhibitor which inhibits the expression of LIPG gene; a ribozyme; an LIPG polypeptide; an enhancer which increases the enzymatic activity of LIPG polypeptide; or an enhancer which increases the expression of LIPG gene. The invention relates also to methods for using the above compositions. In addition, the invention relates to a method for diagnosing a predisposition to lower cholesterol, a method for determining whether a test compound can inhibit the enzymatic reaction between LIPG polypeptide and HDL cholesterol, and methods for determining whether a test compound can enhance the enzymatic reaction between LIPG polypeptide and LDL or VLDL cholesterol.

US Patent:

7056720, Jun 6, 2006

Filed:

Apr 23, 2002

Appl. No.:

10/128449

Inventors:

Michael C. Jaye - Glenside PA, US
Kim-Anh Thi Doan - Audubon PA, US
John A. Krawiec - Gulph Mills PA, US
Kevin J. Lynch - Gurnee IL, US
Dilip V. Amin - Lansdale PA, US
Victoria J. South - Collegeville PA, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

C12N 9/20
C12N 15/55
C12Q 1/44
A61K 38/04
A61K 38/46

US Classification:

435198, 435 19, 435 691, 4352523, 4353201, 424 946, 530326, 536 232

Abstract:

The present invention relates to LLG polypeptides, which are polypeptides of the triacylglycerol lipase family, and fragments thereof, antibodies against such polypeptides, nucleic acids encoding such polypeptides, and antisense nucleic acids derived from such nucleic acids. The invention relates also to therapeutic compositions and methods comprising the above. In addition, the invention relates to the preparation of LLG polypeptides using recombinant technology and to the use of LLG polypeptides to screen for agonists and antagonists thereof.

US Patent:

7579447, Aug 25, 2009

Filed:

Mar 7, 2006

Appl. No.:

11/369410

Inventors:

Michael C. Jaye - Glenside PA, US
Kim-Anh Thi Doan - Audubon PA, US
John A. Krawiec - Gulph Mills PA, US
Kevin J. Lynch - Gurnee IL, US
Dilip V. Amin - Lansdale PA, US
Victoria J. South - Collegeville PA, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

C07K 16/00
C07K 16/40
C12N 5/06
C12N 5/12
A61K 39/395
A61K 39/00

US Classification:

53038825, 5303871, 5303879, 5303881, 53038826, 5303891, 5303893, 4241301, 4241391, 4241411, 4241461, 4241581, 435326, 435338, 435346

Abstract:

Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.

US Patent:

8343494, Jan 1, 2013

Filed:

Jul 15, 2009

Appl. No.:

12/503778

Inventors:

Michael C. Jaye - Glenside PA, US
Kim-Anh Thi Doan - Audubon PA, US
John A. Krawiec - Gulph Mills PA, US
Kevin J. Lynch - Gurnee IL, US
Dilip V. Amin - Lansdale PA, US
Victoria J. South - Collegeville PA, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

A61K 39/00
A61K 39/395

US Classification:

4241461, 4241411, 4241301

Abstract:

Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.

US Patent:

20090208479, Aug 20, 2009

Filed:

Aug 25, 2008

Appl. No.:

12/197970

Inventors:

Michael Jaye - Glenside PA, US
Kim-Anh Thi Doan - Spring City PA, US
John A. Krawiec - Gulph Mills PA, US
Kevin J. Lynch - Gurnee IL, US
Dilip V. Amin - Lansdale PA, US
Victoria J. South - Collegeville PA, US
Dawn Marchadier - Sicklerville NJ, US
Cyrille Maugeais - Philadelphia PA, US
Daniel J. Rader - Collegeville PA, US

International Classification:

A61K 38/46
C12Q 1/60

US Classification:

424 946, 435 11

Abstract:

Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.

US Patent:

20130059361, Mar 7, 2013

Filed:

Dec 12, 2011

Appl. No.:

13/323731

Inventors:

Michael Jaye - Glenside PA, US
Kim-Anh Thi Doan - Spring City PA, US
John A. Krawiec - Gulph Mills PA, US
Kevin J. Lynch - Gurnee IL, US
Dilip V. Amin - Lansdale PA, US
Victoria J. South - Collegeville PA, US
Dawn Marchadier - Sicklerville NJ, US
Cyrille Maugeais - Philadelphia PA, US
Daniel J. Rader - Collegeville PA, US

International Classification:

C12N 9/20
C12N 15/85
C07K 16/40
C07K 2/00
C07H 21/04

US Classification:

435198, 530300, 536 245, 5303891, 4353201

Abstract:

Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.

US Patent:

20130198565, Aug 1, 2013

Filed:

Jan 28, 2011

Appl. No.:

13/575196

Inventors:

Spiros Mancoridis - Philadelphia PA, US
Chris Rorres - Wynnewood PA, US
Maxim Shevertalov - Paoli PA, US
Kevin M. Lynch - Mount Laurel NJ, US
Edward Stehle - Philadelphia PA, US

Assignee:

Drexel University - Philadelphia PA

International Classification:

G06F 11/07
G06N 5/02

US Classification:

714 26

Abstract:

A computational geometry technique is utilized to detect, diagnose, and/or mitigate fault detection during the execution of a software application. Runtime measurements are collected and processed to generate a geometric enclosure that represents the normal, non-failing, operating space of the application being monitored. When collected runtime measurements are classified as being inside or on the perimeter of the geometric enclosure, the application is considered to be in a normal, non-failing, state. When collected runtime measurements are classified as being outside of the geometric enclosure, the application is considered to be in an anomalous, failing, state. In an example embodiment, the geometric enclosure is a convex hull generated in N-dimensional Euclidean space. Appropriate action (e.g., restart the software, turn off access to a network port) can be taken depending on where the measurement values lie in the space.